Or a pharmaceutically acceptable salt, derivative, or prodrug thereof, as defined herein. In certain embodiments, the disclosure relates to a compound having Formula I, This disclosure relates to certain N4-hydroxycytidine and derivatives, combinations, pharmaceutical compositions, and methods related thereto. The compounds and methods disclosed herein addressed these needs. What are needed are new compounds and treatments for viral infections. report evaluations on the efficacy of 2′-C-MeC, 2′-F-2′-C-MeC, and NHC on Norwalk virus. report β-D-N(4)-hydroxycytidine (NHC) was found to have antipestivirus and antihepacivirus activities. Additional studies are needed to further characterize the virus and to identify ways to prevent and treat disease. SARS-CoV-2 entry into the CNS may be promoted through viral interaction with ACE2 receptors after dissemination of the virus in the systemic circulation or across the cribriform plate. COVID-19 can include severe respiratory disease in humans and appears to also cause neurological disease that includes dizziness, impaired consciousness, acute cerebrovascular disease, epilepsy, hyposmia, hypopsia, and neuralgia (medRxiv, 2020, 1-26). SARS-CoV-2/2019-nCoV, causes disease referred to as COVID-19. The 2019-nCoV is a highly pathogenic human pathogen that relatively little is known about. Analysis of a single completed full-genome sequence revealed 2019-nCov belongs to betacoronavirus but is divergent from SARS and MERS. In addition, human-to-human transmission of 2019-nCov has been documented. Reports from early February 2020 indicate more than 28,000 people have been infected with the novel coronavirus, with more than 560 deaths documented. In 2019, a new coronavirus, 2019-nCoV and now known as SARS-CoV-2, was discovered in humans in Wuhan, China. Since 2012, there have been more than 2,500 cases of MERS with 919 deaths. There were more than 8,000 human cases of SARS with 774 deaths. The two previous coronaviruses to emerge and cause human illness were SARS and MERS. BACKGROUNDĬoronaviruses are enveloped positive-sense RNA viruses that cause a large percentage of respiratory illness in humans. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, in particular, 2019-nCoV. This disclosure relates to N4-hydroxycytidine nucleoside and derivatives, as well as compositions and methods related thereto. The government has certain rights in the invention. HDTRA1-13-C-0072 and HDTRA1-15-C-0075 awarded by the Department of Defense and grant nos. This invention was made with government support under grant nos. 7, 2020, each of which are incorporated by reference herein in their entireties. This application claims the benefit of priority to U.S.